Anidulafungin

🧮 Dose calculator

Invasive fungal infection (aspergillosis, candidaemia, cryptococcosis) — hospital · Regimen source: FDA Eraxis · 2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Eraxis · 8.1

  “Risk Summary Based on findings from animal studies, ERAXIS can cause fetal harm when administered to a pregnant woman.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Eraxis · 8.2

  “Risk Summary There are no data on the presence of anidulafungin in human milk, the effects on the breastfed infant or the effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Eraxis · 8.4

  “The safety and effectiveness of ERAXIS for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis, have been established in pediatric patients 1 month of age and older.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Eraxis · 8.5

  “Of the total number of subjects (N = 197) in the pivotal clinical studies of anidulafungin, 35% were 65 years and over, while 18% were 75 years and over.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.